Medical Doctor Program year 2025 Source: CMS Open Payments, 2026 publication

Michael Szymanski

Trauma Surgery Boston, MA Medical Doctor

NPI 1376170662 CMS profile 11912724

85 E Concord St, Boston, MA 02118

Open in the dashboard

General payments

$129

5 records reported · program year 2025

Research payments

$0

Paid to them · None reported · program year 2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Szymanski of Boston, MA is reported in the CMS Open Payments database as having received $129 across 5 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 15th percentile of Trauma Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2025 General $129 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Szymanski
  • Trauma Surgery median
  • Middle half of Trauma Surgery
  • National median

In program year 2025, general payments to Michael Szymanski were reported at $129. Among 762 Trauma Surgery profiles paid that year, the median was $280 and the middle half received between $87 and $1,585.

Show as a table
Year Michael Szymanski Trauma Surgery median Middle half National median
2019 $0 $153 $56–$644 $163
2020 $0 $123 $39–$342 $114
2021 $0 $142 $45–$556 $132
2022 $0 $172 $59–$732 $149
2023 $0 $213 $83–$1,200 $160
2024 $0 $237 $86–$1,280 $164
2025 $129 $280 $87–$1,585 $169

Breakdown

Who paid General payments · program year 2025
  1. Integra LifeSciences Corporation $84 4 payments
  2. Medtronic, Inc. $45 1 payment

Every payment, record by record

What the payments were for General payments · program year 2025
  1. Food and Beverage $129 5 payments
Products named General payments · program year 2025
  1. Integra Recon-Skin And Wound $84 4 payments
  2. Integra Recon-Skin And Wound $84 4 payments
  3. Integra Recon-Skin And Wound $84 4 payments
  4. INTEGRA DERMAL REGENERATION TEMPLATE $84 4 payments
  5. PRIMATRIX $84 4 payments
  6. ENDURANT IIS $45 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

49

Median for General Surgery: 59

Drug cost

$143

Median for General Surgery: $393

Branded share of claims

0%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ibuprofen Generic 29 $92
Gabapentin Generic 20 $51

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Records

5 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Trauma Surgery in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record